Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
Clinical trials are offering new options for cancer patients, with some achieving long-term survival even with advanced disease. Precision medicine programs are expanding access to these trials by identifying patients with specific tumor mutations, reshaping oncology care.
The global radiopharmaceuticals market is projected to reach $12.8B–$21.8B by 2033–2036, driven by cancer therapy demand. Oncology accounts for over 50% of applications, Technetium-99m dominates radioisotopes, and Asia-Pacific leads growth.
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Illuminate 3.0 brought global and Indian oncology experts to Mumbai for a three-day townhall on precision oncology, immunotherapy, cellular therapies and cancer vaccines. Discussions covered CAR-T cell therapy, multi-cancer early detection and access to novel drugs in India.
Genomic technologies including whole-genome sequencing and polygenic risk scores are advancing precision medicine for neurodegenerative diseases like Alzheimer's and Parkinson's. Research reveals complex gene interactions in conditions like PTEN hamartoma tumor syndrome and sex-specific metabolic signatures in Alzheimer's disease. The integration of genomics with molecular neurobiology offers potential for more accurate diagnosis and treatment.
The artificial intelligence in drug discovery market is projected to grow from USD 3.25 billion in 2026 to USD 10.29 billion by 2031, representing a 25.94% CAGR. AI technologies are accelerating drug discovery timelines, reducing costs, and improving success rates through advanced analytics and machine learning. North America leads market adoption while Asia-Pacific emerges as a high-growth region driven by expanding biotechnology sectors.
The global orphan drugs market is projected to grow from $223.76 billion in 2023 to $486.51 billion by 2032, with North America leading at 38% market share. Over 500 orphan drugs are approved with more than 800 candidates in clinical trials, driven by regulatory incentives and major pharmaceutical company investments in rare disease therapies.
